Establishment of standard treatment for pancreatic ductal adenocarcinoma with peritoneal metastasis
Phase 3
Recruiting
- Conditions
- Invasive ductal adenocarcinoma
- Registration Number
- JPRN-jRCTs051180199
- Lead Sponsor
- Satoi Sohei
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 180
Inclusion Criteria
Patients with peritoneal metastasis without other organ metastases
Exclusion Criteria
Cytology positive in patients with resectable/borderiline resectable pancreatic ductal adenocarcinoma
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Overall Survival
- Secondary Outcome Measures
Name Time Method Response rate, negative rate of peritoneal lavage cytology, symptom relief effect, resectability, relative dose intensity, progression-free survival, decreasing rate of tumor marker, safety